Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous adipose-derived mesenchymal stem cells (Steminent Biotherapeutics)
- Development stage
- Unknown
- Lead developer
- Steminent Biotherapeutics
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular
01
Overview
Autologous adipose-derived mesenchymal stem cells (ADMSCs) developed by **Steminent Biotherapeutics** are a cell-based therapeutic candidate being evaluated for the treatment of knee osteoarthritis. The therapy involves harvesting a patient's own adipose tissue, from which mesenchymal stem cells are isolated, expanded in vitro, and then re-administered via intra-articular injection into the affected joint. These cells are thought to exert their therapeutic effects primarily through paracrine signaling, secreting a variety of anti-inflammatory cytokines and growth factors that modulate the immune response, reduce synovial inflammation, and potentially stimulate the repair of damaged articular cartilage. This autologous approach aims to provide a personalized treatment that minimizes the risk of immune rejection while addressing the underlying degenerative processes of osteoarthritis.
- Other names
- autologous ADMSCsadipose-derived mesenchymal stem cellsADMSCs
Beyond the preview
Go deeper on autologous adipose-derived mesenchymal stem cells (Steminent Biotherapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous adipose-derived mesenchymal stem cells (Steminent Biotherapeutics).